Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of lenvatinib丨cas 417716-92-8 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications
| Character: | Off-white to white powder |
| Purity: | 99.0% min |
| Loss on drying: | 0.5% max |
| Residue on ignition: | 0.5% max |
| Unspecified impurity: | 0.2% max |
| Total impurities: | 1.0% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2924199090305 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
-20°C |
|
Condition to Avoid |
|
|
Package |
Applications
1. Cancer Treatment
Lenvatinib is a targeted anticancer drug used in the treatment of various solid tumors. It is approved for use in several types of advanced or metastatic cancers, including:
■ Thyroid Cancer
Approved for radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC).
Improves progression-free survival compared to placebo.
■ Hepatocellular Carcinoma (HCC)
Used as a first-line therapy for unresectable liver cancer.
Shown to be non-inferior to sorafenib in clinical trials (e.g., REFLECT trial).
■ Renal Cell Carcinoma (RCC)
Used in combination with everolimus or pembrolizumab for advanced RCC.
Offers improved objective response rate and overall survival.
■ Endometrial Cancer
Approved in combination with pembrolizumab for advanced or recurrent endometrial carcinoma not responsive to conventional therapy.
Benefits
1. Targeted Therapy
Specifically acts on cancer-driving pathways, minimizing damage to normal cells compared to traditional chemotherapy.
2. Broad Antitumor Activity
Effective across multiple cancer types due to its multi-target inhibition.
3. Oral Administration
Given as a daily oral capsule, which is more convenient than intravenous therapies.
4. Synergistic in Combination Therapy
Potentiates the efficacy of immunotherapies (e.g., pembrolizumab), enabling combinatorial treatment approaches.
5. Improved Clinical Outcomes
Increases progression-free survival (PFS) and overall response rate (ORR) in several cancer types.
Often a first-line choice when surgery is not feasible or disease is refractory to standard care.
Conclusion
Lenvatinib (CAS 417716-92-8) is a potent, multi-targeted kinase inhibitor used in modern oncology. It plays a critical role in the treatment of thyroid, liver, kidney, and endometrial cancers by inhibiting angiogenesis and tumor cell proliferation. Its effectiveness, particularly when combined with immunotherapy, makes it a cornerstone in the management of several difficult-to-treat cancers.

